| Literature DB >> 34616139 |
Friederike C Kortuem1, Focke Ziemssen1,2, Karsten U Kortuem3, Constanze Kortuem1.
Abstract
PURPOSE: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic forced ophthalmologists to adjust their working conditions to ensure patient and staff safety, while still providing effective and timely treatment. This international survey among ophthalmologists was initiated to capture what actions ophthalmologists were taking and what their opinions were on the risks of infection in their workplace, the delay in treatment, the use of telemedicine and telephone for appointments, and the regional specifications and measures implemented by the respective authorities.Entities:
Keywords: COVID-19; infection control; occupational safety; survey
Year: 2021 PMID: 34616139 PMCID: PMC8488052 DOI: 10.2147/OPTH.S327745
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Figure 1Example view of the responsive email template that invited participation in the survey.
Results of the COVID-19 Survey Scale Among Up to 685 Ophthalmologists
| Evaluation of Continents | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Statements | Answers, n (%) | ||||||||||||
| Strongly Agree | Generally Agree | Indifferent | Generally Disagree | Strongly Disagree | Mean (±SD) | Total n | Mean (±SD) Europe (n = 581–583) | Mean (±SD) North America (n = 73–74) | Mean (±SD) South America (n = 9) | Mean (±SD)Asia (n = 11) | Mean (±SD) Oceania (n = 2) | Mean (±SD) Africa (n = 5) | |
| I am very concerned that patients could become infected during my treatment. | 88 (12.85%) | 240 (35.04%) | 97 (14.16%) | 199 (29.05%) | 61 (8.91%) | 2.9 (±1.2) | 685 | 2.9 (±1.2) | 2.5 (±1.3) | 2.4 (±1.0) | 2.8 (±1.5) | 2.0 (±0.0) | 1.6 (±0.6) |
| I fear the consequences of delayed treatment during the pandemic. | 185 (27.01%) | 321 (46.86%) | 93 (13.58%) | 72 (10.51%) | 14 (2.04%) | 2.1 (±1.0) | 685 | 2.2 (±1.0) | 1.7 (±0.9) | 1.3 (±0.5) | 2.1 (±1.2) | 2.0 (±0.0) | 1.0 (±0.0) |
| Phone calls/contact effectively reduce the number of unnecessary examinations. | 80 (11.70%) | 239 (34.94%) | 159 (23.25%) | 159 (23.26%) | 47 (6.87%) | 2.8 (±1.1) | 684 | 2.8 (±1.1) | 2.6 (±1.2) | 3.2 (±1.0) | 2.4 (±1.2) | 2.0 (±0.0) | 3.0 (±1.2) |
| Consultation by phone can reduce the fear of infection at the doctor’s office. | 97 (14.18%) | 347 (50.73%) | 149 (21.78%) | 75 (10.97%) | 16 (2.34%) | 2.4 (±0.9) | 684 | 2.4 (±0.9) | 2.3 (±1.0) | 2.6 (±0.9) | 2.4 (±1.3) | 2.0 (±1.4) | 1.6 (0.6) |
| Consultation by telephone can significantly reduce the rate of non-emergent patients (“no shows”). | 100 (14.64%) | 312 (45.68%) | 165 (24.16%) | 84 (12.30%) | 22 (3.22%) | 2.4 (±1.0) | 683 | 2.5 (±1.0) | 2.3 (±1.0) | 2.4 (±1.0) | 2.2 (±1.0) | 2.0 (±0.0) | 2.6 (1.3) |
| The government of my country/region has reacted sufficiently and sensibly to the pandemic. | 93 (13.64%) | 303 (44.43%) | 106 (15.54%) | 106 (15.54%) | 74 (10.85%) | 2.7 (±1.2) | 682 | 2.5 (±1.1) | 4.0 (±1.3) | 3.2 (±1.4) | 2.6 (±1.4) | 1.0 (±0.0) | 2.4 (±1.5) |
| Even without slit lamp findings and fundus photos, a reliable telemedical evaluation is possible in most cases. | 6 (0.88%) | 79 (11.57%) | 101 (14.79%) | 327 (47.88%) | 170 (24.89%) | 3.8 (±1.0) | 683 | 3.9 (±0.9) | 3.7 (±1.1) | 3.8 (±1.2) | 3.7 (±1.1) | 3.5 (±0.7) | 3.6 (±1.1) |
Patients Seen Before the Pandemic (Categories: 1: <50; 2: 50–100; 3: 101–150; 4: 151–200; 5: >200) and Perceived Mean Reduction Due to the COVID-19 Pandemic Depending on Continent, Gender, Age and Experience
| Mean Patients per Week | Mean Reduction in Patients ±SD | |
|---|---|---|
| Europe | 3.2 ± 1.3 (n = 583) | 20.1 ± 17.6 (n = 583) |
| North America | 2.1 ± 0.9 (n = 74) | 32.6 ± 20.4 (n = 74) |
| South America | 2.4 ± 0.7 (n = 9) | 32.2 ± 15.4 (n = 9) |
| Asia | 3.0 ± 1.7 (n = 11) | 33.9 ± 18.7 (n = 11) |
| Africa | 2.2 ± 0.8 (n = 5) | 43.0 ± 17.9 (n = 5) |
| Oceania | 2.0 ± 0 (n = 2) | 17.5 ± 17.7 (n = 2) |
| Female | 3.0 ± 1.2 (n = 351) | 21.2 ± 18 (n = 351) |
| Male | 3.1 ± 1.3 (n = 331) | 22.9 ± 18.8 (n = 332) |
| Age not indicated | 2.7 ± 1.4 (n = 17) | 25.2 ± 15.8 (n = 17) |
| Age 21–30 | 2.5 ± 1.0 (n = 66) | 18.0 ± 14.4 (n = 66) |
| Age 31–40 | 2.9 ± 1.2 (n = 178) | 20.7 ± 18.1 (n = 178) |
| Age 41–50 | 3.0 ± 1.3 (n = 162) | 23.9 ± 20.8 (n = 163) |
| Age 51–60 | 3.4 ± 1.3 (n = 174) | 21.7 ± 18.0 (n = 174) |
| Age >60 | 3.1 ± 1.3 (n = 86) | 24.2 ± 18.3 (n = 84) |
| Less than 5 years | 2.5 ± 1.1 (n = 113) | 20.3 ± 17.2 (n = 113) |
| 5–10 years | 2.9 ± 1.2 (n = 109) | 21.0 ± 17.8 (n = 110) |
| 10–20 years | 3.1 ± 1.3 (n = 169) | 21.9 ± 18.8 (n = 169) |
| 20–40 years | 3.3 ± 1.3 (n = 271) | 23.11 ± 19.1 (n = 271) |
| Over 40 years | 2.7 ± 1.3 (n = 21) | 22.3 ± 18.6 (n = 21) |
Results of Scale of Satisfaction with the Respective Governments of Different Countries (Only Countries with at Least 10 Answers are Shown) and Their Deaths per Million Capita Due to SARS-CoV-2 Infection Cited on the 15th of July 2021 (Source Statista11); Strongly Agree: 1; Generally Agree: 2 Indifferent: 3; Generally Disagree: 4; Strongly Disagree: 5
| Country | Mean ± SD Satisfaction with Government | Deaths per 1 Million Capita |
|---|---|---|
| Austria (n = 22) | 2.6 ± 0.9 | 1201.1 |
| Germany (n = 456) | 2.4 ± 1.0 | 1081.9 |
| Italy (n = 10) | 3.5 ± 1.6 | 2106.8 |
| Mexico (n = 49) | 4.3 ± 1.1 | 1804.3 |
| Switzerland (n = 17) | 2.9 ± 1.1 | 1266.6 |
| UK (n = 15) | 2.8 ± 1.2 | 1909.8 |
| USA (n = 23) | 3.5 ± 1.5 | 1819.5 |